REFILE-BioMarin Pharma gets DOJ subpoena on certain drug testing programs

Reuters

Updated Mon, Feb 26, 2024, 6:42 PM

In this article:

(Corrects to fix typographical error in story identifier)

Feb 26 (Reuters) - BioMarin Pharmaceutical has received a subpoena from the U.S. Department of Justice seeking information about the company's sponsored testing programs related to two treatments, it said in a filing on Monday.

BioMarin did not immediately respond to a Reuters request seeking additional information. (Reporting by Pratik Jain; Editing by Pooja Desai)

Trump to set interest rates himself under secret presidential plan
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
The Telegraph•16h ago
Walmart CEO started his career unloading trailers at the warehouse—he says he got promotion after promotion by raising his hand when his boss was out of town
Walmart's CEO went from earning $6.50 an hour to $25 million a year—here are his three tips for climbing the corporate ladder like him
Fortune•23h ago
2 Stock-Split Stocks to Buy Hand Over Fist Right Now
These proven wealth builders could be exactly what you're searching for right now.
Motley Fool•20h ago
Analysts revamp Microsoft stock price target after earnings
Here's what could happen next to Microsoft shares.
TheStreet•11h ago
Housing supply surges by up to 50% in these metro areas — and many sellers are being forced to slash their asking prices
The property report includes 85 major metropolitan areas in the U.S. with populations of at least 750,000.
MarketWatch•1d ago
Bank of America lays out the exact scenario that could finally pop the stock market's AI bubble
It's been an "everything buy bonds" bull rally in markets for months, but BofA is cautiously watching a couple of indicators.
Business Insider•9h ago
U.S. panic over national debt might mark a culture shift—are Americans becoming more ‘European’ about money?
Jamie Dimon and Jerome Powell are taking the European viewpoint on soaring debt levels in the U.S.
Fortune•22h ago
4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Opportunistic investors can still find bargains, even with the Nasdaq Composite up 49% since the start of 2023.
Motley Fool•37m ago
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks
Put your money to work by investing in these three high-quality dividend stocks.
Motley Fool•22h ago
Departing top Tesla exec cashes out almost his entire stake for $181 million as longtime bull Ron Baron calls bottom in the stock
Baron, whose largest position is in Tesla, is betting the new shift in strategy for Tesla’s low-cost car will fill its increasingly empty factories.
Fortune•22h ago

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

REFILE-BioMarin Pharma gets DOJ subpoena on certain drug testing programs

Recommended Stories

Trump to set interest rates himself under secret presidential plan

Walmart CEO started his career unloading trailers at the warehouse—he says he got promotion after promotion by raising his hand when his boss was out of town

2 Stock-Split Stocks to Buy Hand Over Fist Right Now

Analysts revamp Microsoft stock price target after earnings

Housing supply surges by up to 50% in these metro areas — and many sellers are being forced to slash their asking prices

Bank of America lays out the exact scenario that could finally pop the stock market's AI bubble

U.S. panic over national debt might mark a culture shift—are Americans becoming more ‘European’ about money?

4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

Want $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks

Departing top Tesla exec cashes out almost his entire stake for $181 million as longtime bull Ron Baron calls bottom in the stock